TY - JOUR
T1 - Comprehensive registry of esophageal cancer in Japan, 2015
AU - The Registration Committee for Esophageal Cancer of the Japan Esophageal Society
AU - Watanabe, Masayuki
AU - Toh, Yasushi
AU - Ishihara, Ryu
AU - Kono, Koji
AU - Matsubara, Hisahiro
AU - Miyazaki, Tatsuya
AU - Morita, Masaru
AU - Murakami, Kentaro
AU - Muro, Kei
AU - Numasaki, Hodaka
AU - Oyama, Tsuneo
AU - Saeki, Hiroshi
AU - Tanaka, Koji
AU - Tsushima, Takahiro
AU - Ueno, Masaki
AU - Uno, Takashi
AU - Yoshio, Toshiyuki
AU - Usune, Shiyori
AU - Takahashi, Arata
AU - Miyata, Hiroaki
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2023/1
Y1 - 2023/1
N2 - Background: The registration committee for esophageal cancer in the Japan Esophageal Society (JES) has collected the patients' characteristics, treatment, and outcomes of patients who underwent any treatment during 2015 in Japan. Methods: We analyzed patients' data who had visited the participating hospitals in 2015. We collected the data using the National Clinical Database with a web-based data collection system. We used the Japanese Classification of Esophageal Cancer 10th edition by JES and the TNM classification by the Union of International Cancer Control (UICC) for cancer staging. Results: A total of 9368 cases were registered from 355 institutions in Japan. Squamous cell carcinoma and adenocarcinoma accounted for 86.7% and 7.4%, respectively. The 5-year survival rates of patients treated by endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, and esophagectomy were 87.2%, 33.5%, 24.2%, and 59.9%, respectively. Esophagectomy was performed in 5172 cases. Minimally invasive approaches were selected for 60.6%, and 54.4% underwent thoracoscopic esophagectomy. The operative mortality (within 30 days after surgery) was 0.79% and the hospital mortality was 2.3%. The survival curves showed an excellent discriminatory ability both in the clinical and pathologic stages by the JES system. The survival of pStage IV was better than IIIC in the UICC system because pStage IV included the patients with supraclavicular lymph node metastasis (M1 LYM). Conclusion: We hope this report improves all aspects of diagnosing and treating esophageal cancer in Japan.
AB - Background: The registration committee for esophageal cancer in the Japan Esophageal Society (JES) has collected the patients' characteristics, treatment, and outcomes of patients who underwent any treatment during 2015 in Japan. Methods: We analyzed patients' data who had visited the participating hospitals in 2015. We collected the data using the National Clinical Database with a web-based data collection system. We used the Japanese Classification of Esophageal Cancer 10th edition by JES and the TNM classification by the Union of International Cancer Control (UICC) for cancer staging. Results: A total of 9368 cases were registered from 355 institutions in Japan. Squamous cell carcinoma and adenocarcinoma accounted for 86.7% and 7.4%, respectively. The 5-year survival rates of patients treated by endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, and esophagectomy were 87.2%, 33.5%, 24.2%, and 59.9%, respectively. Esophagectomy was performed in 5172 cases. Minimally invasive approaches were selected for 60.6%, and 54.4% underwent thoracoscopic esophagectomy. The operative mortality (within 30 days after surgery) was 0.79% and the hospital mortality was 2.3%. The survival curves showed an excellent discriminatory ability both in the clinical and pathologic stages by the JES system. The survival of pStage IV was better than IIIC in the UICC system because pStage IV included the patients with supraclavicular lymph node metastasis (M1 LYM). Conclusion: We hope this report improves all aspects of diagnosing and treating esophageal cancer in Japan.
KW - Cancer registry
KW - Chemoradiotherapy
KW - Chemotherapy
KW - Endoscopic resection
KW - Esophageal cancer
KW - Esophagectomy
UR - http://www.scopus.com/inward/record.url?scp=85138922499&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138922499&partnerID=8YFLogxK
U2 - 10.1007/s10388-022-00950-5
DO - 10.1007/s10388-022-00950-5
M3 - Article
C2 - 36152081
AN - SCOPUS:85138922499
SN - 1612-9059
VL - 20
SP - 1
EP - 28
JO - Esophagus
JF - Esophagus
IS - 1
ER -